Fraud Is A Symptom Of A Deeper Flaw

Two recent congressional investigations of “scientific fraud” (The Scientist, July 11, page 1) have rekindled a dispute about what it is, what causes it, and what to do about it. The current debate focuses narrowly on whether federal agencies will be required to develop and administer regulations, or whether universities can formulate and administer their own guidelines without external pressures. The record seems to indicate that external regulation is needed, because universit

Written byLeonard Minsky
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Two recent congressional investigations of “scientific fraud” (The Scientist, July 11, page 1) have rekindled a dispute about what it is, what causes it, and what to do about it. The current debate focuses narrowly on whether federal agencies will be required to develop and administer regulations, or whether universities can formulate and administer their own guidelines without external pressures.

The record seems to indicate that external regulation is needed, because universities are evidently quite far from practicing the ethics they preach at congressional hearings. Indeed, in case after case, the universities have consistently preferred cover-up to investigation. They have attacked the reputations of witnesses and whistle-blowers rather than admit that misconduct was committed.

But the current debate doesn’t probe deeply enough into the problem. Despite the protestations of universities, scientific fraud is not just a matter of individual acts perpetuated by a few misguided scientists. Instead, fraud and misconduct ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies